INJECTION INDEXWeight management, clearly.
The online care edition
October 2026
Offer profile · October 7, 2026

Enhance.MD Review

Enhance.MD’s introductory offer needs its continuing charge and supply period; combined-drug marketing is not approval or superiority evidence.

Article updated

Read this firstArticle updated November 13, 2026; source dates below

Read the dated Enhance.MD update before budgeting beyond an introductory charge.

Introductory card
$112

See supply note.

Continuing card
$212

See supply note.

Enhance.MD’s menu distinguishes an introductory price from an ongoing rate. The dated update below records the newly observed cards and the limits of that observation. The financial question remains what is collected first, what is charged later and how much medication each supply contains.

The page also names several other compounded offerings, including tirzepatide and a semaglutide-plus-tirzepatide combination. These are distinct advertised preparations. This review describes their commercial and evidence boundaries without endorsing a combination or suggesting an individual treatment choice.

Update ·

November 13 source note: cards and supply period

November 13 Enhance.MD introductory/continuing cards: semaglutide $112/$212; tirzepatide $180/$280. Four-week supplies had monthly labels. EverPrime’s transition banner linked only to a page fragment.

These observations replace the old introductory figures as a starting record, not a selected billing agreement. Obtain the collection interval, shipment schedule and renewal in writing. We did not establish transfer terms or a replacement offer. The chart reflects the observed cards; earlier arithmetic is superseded.

Sources for this update

The details, visualized

Enhance.MD semaglutide cards — November 13

Advertised US dollars; billing scope shown on every row

  1. Introductory card$112

    See supply note.

  2. Continuing card$212

    See supply note.

November 13, 2026: four-week supplies labeled monthly; selected collection dates unverified.

View the printable chart imageEnhance.MD semaglutide cards — November 13. The same values and context are available in the data table above.
Research note 01

Recalculate from the selected collection schedule

Build a new calculation from the selected quote: list the first collection, each continuing collection and the supply period. Keep four weeks separate from a calendar month. Do not extend an introductory rate across later payments; add only the charges confirmed in the agreement. The earlier calculation is superseded.

The site also presents other treatment menus. Do not attach a different medicine’s price or laboratory schedule to the semaglutide promotion without checking its exact details. The selected preparation, included services and eligibility conditions belong with the price calculation.

Research note 02

Follow-up should be specific to the prescription

Enhance.MD describes continuing provider support and a refund when onboarding determines that medication is inappropriate. Ask how later treatment changes are handled and which charges can continue if medication pauses. A clinical check-in and a subscription renewal should be visible as separate events.

Before you decide

Questions worth answering

What is the most useful detail to verify before choosing Enhance.MD?

Read the dated Enhance.MD update before budgeting beyond an introductory charge. Save the selected product name, payment or supply period, and the source or agreement that confirms it. A written record makes later changes easier to identify.

Does this review establish how much weight I would lose?

No. This is a review of public offer information, including its billing and service model. A provider advertisement, testimonial, or trial of a branded medicine does not establish the outcome of an individual order from Enhance.MD.

Evidence behind this page

Sources & chart notes

Source dates are listed with each document. Earlier research and later offer updates are identified separately. Provider pages establish advertised terms. Labels and trial reports describe specific medicines and study populations. Medical review has not been completed.

Editorial illustration: a telehealth screen, a question card and an unbranded container.
Enhance.MD Review — keep the product information and the route for asking a question in the same comparison.

The introductory charge is not the continuing amount

Keep each medicine and payment stage together rather than mixing the lowest initial figure with another treatment’s features. Use the dated card observation above as a starting record, then obtain the complete selected agreement. A continuing advertised rate does not establish the exact renewal date or collection schedule for an individual order.

The panels describe medication, ongoing provider care and periodic metabolic laboratory testing among the features. These are advertised inclusions. A complete selected agreement would still clarify the billing interval, renewal and any additional services. The cost guide follows that distinction.

Editorial illustration: an unbranded container, information sheet and magnifying glass.
The first month is not the continuing amount — keep the exact product identity and its complete label together.

The combination is a different preparation

GLP-1 Elite is advertised as semaglutide plus tirzepatide, with its own initial and continuing rates. The page describes a rationale about receptor pathways and greater benefit. That is the brand’s marketing explanation, not a controlled comparison establishing the current combined product’s clinical superiority.

The exact named preparation needs its own evidence. Approval or trials for a separately manufactured branded medicine cannot simply be extended to a compounded combination. The treatment guide explains the approval boundary without providing a protocol for any of these products.

The professional review remains conditional

The disclosure says prescription products require consultation with a healthcare professional who determines whether prescribing is appropriate. It also explicitly states that the compounded medication is not FDA-approved and that its safety or effectiveness has not been verified by FDA.

The product imagery is marked as marketing rather than the actual vial. That makes the dispensing label another necessary record, not something the illustration authenticates. This review has not completed an intake or established that a particular advertised preparation is available or appropriate for the reader.

Editorial illustration: a telehealth screen, a question card and an unbranded container.
The professional review remains conditional — keep the product information and the route for asking a question in the same comparison.

A useful quote preserves both time and identity

Enhance.MD’s visible continuing amounts make its introductory offers more interpretable. The unresolved questions concern the complete selected terms and evidence for the exact formula. A low entry rate and a broad metabolism claim answer different questions and should not be used to strengthen each other.

The SnagRx review follows a flat-pricing claim, while Trimi separates an annual equivalent from upfront payment. The renewal guide makes those models comparable without declaring any advertised preparation a clinical winner.

Focused comparisons for this offer

See Cheapest semaglutide injection plans: offers with the whole bill visible · Cheapest tirzepatide injection plans: offers beyond the lowest monthly number · Best GLP-1 programs for first-time patients: routes before the first supply.

Compare another model

SnagRx · BetterMe Rx · Wegovy · Zepbound

The invoice guide and product-status guide explain the distinctions behind these entries.

Research record

Documents used

Original references are retained below. Later observations and their source dates are identified in the dated updates and research notes. Advertising describes an offer; it is not independent verification of treatment outcomes.

  1. Enhance.MD: Official program and offer information ↗
  2. FDA: Concerns with unapproved GLP-1 drugs ↗